Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism

In Vivo

Volumn 12, Issue 2, 1998, Pages 223-231

  Ara, Gulshan ^a   Gravelin, Laura M ^a   Kaddurah Daouk, Rima ^b   Teicher, Beverly A ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Avicena Group Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Creatine; Cyclocreatine; GLUT 4; Insulin; Somatostatin

Indexed keywords

ANTINEOPLASTIC AGENT; CREATINE PHOSPHATE; CYCLOCREATINE; GLUCAGON; GLUCOSE; GLUCOSE TRANSPORTER; GUANIDINOPROPIONIC ACID; INSULIN; PANCREAS HORMONE; SOMATOSTATIN; SUGAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; NONHUMAN; RAT; SOMATOSTATIN BLOOD LEVEL;

EID: 0031834715     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Aguilar-Biyan L, Nichols C, Wechsler S, Clement J, Boyd A, Gonsalez G, Herrera-Sosa H, Nguy K, Bryan J and Nelson D: Cloning of the ß cell highaffinity sulfonylurea receptor: a regulator of insulin secretion. Science 268: 423-425, 1995.
2. Ara G and Teicher B: Relationship of cellular energy parameters to cytotoxicity for AG-17, lonidamine and cyclocreatine in four human tumor cell lines. Int J Oncology 8: 865-873, 1996.
3. Barth E, Stammler G, Spesier B, and Scahper J: Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 24: 669-681, 1992.
4. Bates P, Fisher R, Ward A, Richardson L, Hill D and Graham, C: Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II). Br J Cancer 72: 1189-1193, 1995.
5. Birnbaum M: Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell 57: 305-315, 1989.
6. Bogden A, Esber H, Taylor D and Gray J: Comparative study on the effects of surgery, chemotherapy and immunotherapy, alone or in cimbination on metastases of the 13762 mammary adenocarcinoma. Cancer Res 34: 1627-1631, 1974.
7. Brazeau P Vale W, Burgus R, Ling N, Butcher M, Rivier J and Guillemin R: Hypothalamic polypeptide that inhibits the secretion immunoreactive pituitary growth factor. Science 179: 77-79, 1973.
8. Buscail L, Delesque N, Esteve J, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell G, Liebow C, Schally A, Vaysse N and Susani C: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Nat Acad Sci USA 91: 2315-2319, 1994.
9. Butler W, Kelsey W and Goran N: Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens. Cancer Res 41: 82-88, 1981.
10. Cattaneo M, Smoroso D, Gussoni G, Sanguini A and Vicentini L: A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Letters 397: 164-168, 1996.
11. Charron M, Brosius F, Alper S and Lodish H: A glucose transport protein expressed predominantly in insulin-responsive tissues. Proc Natl Acad Sci 86: 2535-2539, 1989.
12. Detimary P, Gilon P, Nenquin M and Henquin J: Two sites of glucose control of insulin release with distinct dependence on the energy state in pancreatic B-cells. Biochem J 297: 455-461, 1994.
13. Evans A, Crook T, Laws S, Gough A, Royle G and Primrose J: Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Brit J Cancer 75: 798-803, 1997.
14. Figueroa J, Sharma J, Jackson J, McDermott M, Hilsenbeck S and Yee D: Recombinant insulin-like groath factor binding protein-1 inhibits IGF-1, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Phys 157: 229-236, 1993.
15. Fitch C, Jellinek M, Fitts R, Baldwin K and Holloszy J: Phosphorylated ß-guanidinopropionate as a substitute fro phosphocreatine in rat muscle. Am J Physiol 228: 1123-1125, 1975.
16. Fitch C, Jellinek M and Mueller E: Experimental depletion of Creatine and phosphocreatine from skeletal muscle. J Biol Chem 249: 1060-1063, 1974.
17. Fitch C, Lucy D, Bornhofen J and Dalrymple G: Creatine metabolism in skeletal muscle II. Neurology 18: 32-42, 1968a.
18. Fitch C and Sheilds R: Creatine metabolism in skeletal muscle. J Biol Chem 241: 3611-4, 1966.
19. Fitch C, Sheilds R, Payne W and Dacus J: Creatine metabolism in skeletal muscle 3. J Biol Chem 243: 2024-7, 1968b.
20. Fukumoto H, Kayano T, Buse J, Edwards Y, Pilch P, Belle G and Seino S: Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. J Biol Chem 264: 7776-7779, 1989.
21. Gerbitz K, Gempel K and Brdiczka D: Mitochondria and diabetes. Genetic, biochemical and clinical implications of the cellular energy circuit. Diabetes 45: 113-126, 1996.
22. Gibson S and Hilf R: Regulation of estrogen-binding capacity by insulin in 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Cancer Res 40: 2343-2348, 1980.
23. Hofland L, Visser-Wisselaar H and Lamberts S: Somatostatin analogs: clinical application in relation to human somatostain receptor subtypes. Biochem Pharma 50: 287-297, 1995.
24. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ and Kaddurah-Daouk R: Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res 15: 1339-1347, 1995.
25. Inagaki N, Gonoi T, Clement J, Namba N, Inazawa J, Gonsalez G, AguilarBryan L, Seino S and Bryan J: Reconstitution of Ikapt: an inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166-1169, 1995.
26. James D, Strube M and Mueckler M: Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature 338: 83-87, 1989.
27. Kaestner K, Christy R and MeLenithan J: Sequence, tissue distribution and differnetial expression of mRNA for a putative insulin-responsive glucose transporter in 3T3-L1 adipocytes. Proc Nat Acad Sci USA 86: 3150-3154, 1989.
28. Kaufman A, Khazaie K, Wiedemuth M, Rohde-Schulz B, Ullrich A, Schirrmacher V and Lichtner R: Expression of epidermal growth factor receptor correlates with metastatic potential of 13762NF rat mammary adenocarcinoma cells. Int J Oncology 4: 1149-1155, 1994.
29. Ker G, Erchegyi J, Horvath A, Mezo I, Idei M, Vantus T, Balogh A, Vadasz Z, Seprodi J, Teplan I, Csuka O, Tejeda M, Gaal D, Szende B, Roze C, Kalthoff H and Ulrich A: A tumor-selective somatostatin analog (TT-232) with strong in vivo and in vitro antitumor activity. Proc Nat Acad Sci USA 93: 12513-12518, 1996.
30. Lillie JW, O'Keefe M, Valinski H, Hamlin Jr HA, Varban ML and Kaddurah-Daouk R: Cyclocreatine, 1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. Cancer Res 53: 3172-3178, 1993.
31. LoPresti P and Cohn M: Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine as substrate. Biochim Biophys Acta 998: 317-320, 1989.
32. Martin K, Winslow E, O'Keefe M, Khandekar V, Hamlin A, Lillie J and Kaddurah-Daouk R: Specific targeting of tumor cells by the creatine analog cyclocreatine. Int J Oncology 9; 993-999, 1996.
33. Meglasson M, Nelson J and Erecinska M: Bioenergetic response of pancreatic islets to stimulation by fuel molecules. Metabolism 38: 1188-1195, 1993.
34. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer M, Vigneri R, Goldfine I and Belfiore A: Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52: 3924-3930, 1992.
35. Miller EE, Evan AE and Cohn M: Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Nat Acad Sci USA 90: 3304-3308, 1993.
36. Neri A, Welch D, Kawaguchi T and Nicolson G: Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. JNCI 68: 507-17, 1982.
37. Nichols C, Shyng S, Nestorowicz A, Glaser B, Clement J, Gonsalez G, Aguilar-Bryan L, Permutt M and Bryan J: Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 272: 1785-1787, 1996.
38. Ohta M, Nelson D and Meglasson M: Relationships between energy level and insulin secretion in isolated rat islets of Langerhans. A study at various pH levels. Biochem Pharmacol 42: 593-598, 1991.
39. Weckbecker G, Liu R, Tolcsval L and Bruns C: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52: 4973-4978, 1992.
40. Panten U, Zunkler B, Scheit S, Kirchoff K. and Lenzen S: Regulation of energy metabolism in pancreatic islets by glucose and tolbutamide. Diabetologia 29: 648-654, 1986.
41. Payne R and Strauss A: Expression of the mitochondrial creatine kinase genes. Mol Cell Biochem 133: 235-244, 1994.
42. Petrofsky J and Fitch C: Contractile characteristics of skeletal muscle depleted of phosphocreatine. Pflugers Arch 384: 123-129, 1980.
43. Ramasastry S, Weinstein L, Zerbe A, Narayanan K, LaPietra D and Futrell J: Regression of local and distant tumor growth by tissue expansion: an experimental study of mammary carcinoma 13762 in rats. Plast Recon Surg 87: 1-7, 1991.
44. Redding T and Schally A: Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers. In: Hormones, Cell Biology, and Cancer: Perspectives and Potentials, pp. 217-240, Alan R. Liss, 1988.
45. Ren J, Semenkovich C and Holloszy J: Adaptation of muscle to creatine depletion: effect on GLUT-4 glucose transporter expression. Amer J Physiol 264: 146-150, 1993.
46. Reubi J, Horisberger U and Laissue J: High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction. Int J Cancer 56; 681-688, 1994.
47. Saks V, Ventura-Clapier R and Aliev M: Metabolic control and metabolic capacity: two aspects of creatine kinase functioning in the cells. Biochim Biophys Acta 1274: 81-88, 1996.
48. Sauer L, Stayman J and Dauchy R: Amino acid, glucose and lactic acid utilization in vivo by rat tumors. Cancer Res 42: 4090-4097, 1982.
49. Schaer J, Waser B, Mengod G and Reubi J: Somatostatin receptor subtypes sst1, sst2, sst3, and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70: 530-537, 1997.
50. Schimmel L, Khandekar V, Martin K, Riera T, Honan C, Shaw D and Kaddurah-Daouk R: The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. Antcancer Res 16: 375-380, 1996.
51. Setyono-Han B, Henkelman M, Foekens J and Kiljn J, Direct inhibitory effetcs of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566-1570, 1987.
52. Shafer G: On the mechanism of action of hypoglycemia-producing biguanides. A reevaluation and a molecular theory. Biochem Pharma 25: 2005-2014, 1976.
53. Shafie S, Gibson S and Hilf R: Effect of insulin and estrogen on hormone binding in the 8230C mammary adenocarcinoma. Cancer Res 37: 4641-4649, 1977.
54. Shafie S and Hilf R: Relationship between insulin and estrogen binding to growth response in 7,12-dimethylbenx(a)anthracene-induced rat mammary tumors. Cnacer Res 38: 759-764, 1978.
55. Shally A: Oncologial apllications of somatostatin analogues. Cancer Res 48: 6977-6985, 1988.
56. Sheilds R and Whitehair C: Muscle creatine: in vivo depletion by feeding ß-guanidinopropionic acid. Canadian J Biochem 51: 1046-1049, 1973.
57. Shoubridge E, Challis R, Hayes D and Radda G: Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue ß-guanidinopropionic acid. Biochem J 232: 125-131, 1985.
58. Shoubridge E and Radda G: A 31P-nuclear magnetic resonance study of skeletal muscle metabolism in rats depleted of creatine with the analogue betaguanidinopropionic acid. Biochim Biophys Acta 805: 79-88, 1984.
59. Surmacz E and Burgand J: Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1: 1429-1436, 1995.
60. Teicher BA, Menon K, Northey D, Liu J, Kufe DW and Kaddurah-Daouk R: Cyclocreatine in cancer chemotherapy. Cancer Chemother Pharmacol 35: 411-416, 1995.
61. Valkerma R, Steens J, Cleton F and Pauwels E: The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 122: 513-532, 1996.
62. VanDeursen J, Heerschap A, Oerlemans F, Ruitenbeek W, Jap P, tenLaak H and Wieringa B: Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell 74: 621-631, 1993.
63. VanDeursen J, Ruitenbeek W, Heerschap A, Jap P, Laak HT and Wieringa B: Creatine kinase (CK) in skeletal muscle muscle energy metabolism: a study of mouse mutants with graded reduction in muscle CK expression. Proc Natl Acad Sci 91: 9019-9095, 1994.
64. Veech R, Lawson J, Cornell N and Krebs H: Cytosolic phosphorylation potential. J Biol Chem 254: 6538-6547, 1979.
65. Wallimann T and Hemmer W: Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem 133: 193-220, 1994.
66. Westley B and May F: Insulin-like growth factors: the unrecognised oncogenes. Brit J Cancer 72: 1065-1066, 1995.
67. Wheeler T and Hinkle P: The glucose transporter of mammalian cells. Ann Rev Phys 47: 503-517, 1985.
68. White M and McCubrey J: Changes in glucose transport associated with malignant transformation (review). Int J Oncology 7: 701-702, 1995.
69. Woltering E, Barrie R, O'Dorisio T, Arce D, Ure T, Cramer A and Holmes D: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrnae. J Surg Res 50: 245-251, 1991.
70. Zarghami N, Gia M, Yu H, Roagna R, Ponzone R, Katsaros D, Simondi P and Diamandis E: Creatine kinase BB isoenzyme levels in tumour cytosols,. and survival of breast cancer patients, 1995.